Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

PURPOSE: Targeted hepatocellular carcinoma therapy was carried out to improve the efficacy of liver cancer treatment. The purpose of this study was to design an N-acetylgalactosamine (NAcGal) modified and pH sensitive doxorubicin (DOX) prodrug (NAcGal-DOX) for the construction of lipid nanoparticles...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Wendu, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047861/
https://www.ncbi.nlm.nih.gov/pubmed/30034219
http://dx.doi.org/10.2147/DDDT.S166402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047861/
https://www.ncbi.nlm.nih.gov/pubmed/30034219
http://dx.doi.org/10.2147/DDDT.S166402

Ejemplares similares